Mélanie Thill-Tayara
Dechert (Paris)
Lawyer (Partner)
Mélanie Thill-Tayara is a partner in Dechert’s Paris office and co-lead of the firm’s Life Sciences practice. She focuses her practice on antitrust and competition law, and she regularly represents leading companies in merger notifications before the French and European regulators and coordinates multi-jurisdictional filings. She has handled a significant number of cartel and abuse of dominant position cases before EU and French authorities and courts. Prior to joining Dechert in February 2016, she served as a partner for more than 20 years with two other international law firms. Before that she was an officer at the European Commission, Directorate General for Competition, where she participated in numerous dawn raid operations and contributed to several decisions. Mélanie Thill-Tayara is named Top Woman in Antitrust and listed as a leading competition lawyer in France in 2016, she is also recommended as one of the top competiton and antitrust practices in France (2019). She is recognized as a leading lawyer by Who’s Who Legal and by Best Lawyers France 2019. Her team received the Golden Award for Antitrust in France at the Trophées du Droit 2019.
Distinctions
Auteurs associés
Frédéric Jenny
ESSEC Business School (Cergy)
Eric David
Nest Avocats (Paris)
Emmanuelle Claudel
University Paris II Panthéon‑Assas
Carole Champalaune
Ministère de la Justice (Paris)
Marta Giner Asins
Norton Rose Fulbright (Paris)
Bruno Lasserre
French State Council (Paris)
Peter Freeman
UK Competition Appeal Tribunal (London)
Wouter Wils
European Commission (Brussels)
27728 | Conférences
Articles
3176 Bulletin
2312
The pharmaceutical sector stands out as being regularly under the scrutiny of competition authorities throughout Europe and has continued to be a key enforcement priority over the past 18 months, with notable developments in pay-for-delay and excessive pricing cases, as well as on market definition and lifecycle management practices.
322
On 12 December 2018, the General Court (“Court”) partially annulled the European Commission’s decision of 9 July 2014 in the Servier case and consequently reduced Servier’s fine by more than 30%, from €330.99 million to €228.32 million. After the Lundbeck judgment of 8 September 2016, this second (...)
101
The General Court of the European Union recently held, in Goldman Sachs v. Commission, that purely financial investors such as investment funds may be held jointly and severally liable for competition law violations implemented by their portfolio companies when they can exercise “decisive (...)
158
EU Court Orders New Assessment of Intel’s Rebates The Court of Justice of the European Union (CJEU) has quashed a ruling by the EU’s General Court which had upheld the European Commission’s (EC) 2009 finding of abuse of dominance by Intel Corporation Inc. Intel was fined €1.06 billion, a record at (...)
283
The new “Hamon Law” introducing French class actions and its effects on competition and distribution law Introduction In order to balance the powers of economic stakeholders, France has adopted a new consumer law, popularly known as the “Hamon Law”. The new statute, adopted by the French (...)
3001 Revue
283
Les présentes contributions ont été rassemblées à la suite de la 10ème édition de la conférence annuelle “Demain la concurrence” organisée par la Revue Concurrences le 14 juin 2019, au Ministère de l’Économie et des Finances à Paris. Les débats s’organisaient autour de quatre thèmes. Les membres de la (...)
224
La procédure d’engagements présente un intérêt certain pour les entreprises suspectées d’avoir enfreint le droit de la concurrence, qui évitent ainsi une investigation approfondie et une potentielle amende. Du point de vue des autorités de concurrence, elle constitue également un outil efficace (...)
892
Interview réalisée par Mélanie Thill-Tayara, Associée, Dechert, Paris. Diplômé de l’Institut d’études politiques de Paris et de l’ENA, vous avez occupé plusieurs postes au sein de la DGCCRF, travaillé pour la Représentation permanente de la France auprès de l’Union européenne et, moins classique, avez (...)
978
Ce dossier réunit 3 contributions sur les développements récents dans le secteur pharmaceutique. Pour Me Thill-Tayara, avocate chez Dechert Paris et auteur de la première contribution, si l’activisme des autorités de concurrence est motivé, au moins en partie, par le besoin de limiter les dépenses des (...)
624
La troisième table-ronde de la conférence “Demain la concurrence” du 21 février 2014 à Paris, était dédiée au “Règlement 1/2003 et Réseau européen de concurrence 10 ans après : Faut-il étendre la cooperation au contrôle des concentrations et à l’advocacy ?”. Les objectifs pour les auteurs de cette table ronde (...)
